[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cerebral-palsy-dyskinetic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cerebral-palsy-dyskinetic":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,54,82,153],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":36,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100558681","phase-1-pharmacogenomic-contributions-to-trihexyphenidyl-biotransformation-and-response-in-children-with-dystonic-cerebral-palsy-100558681",false,"NCT06554288","Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral Palsy","Pharmacogenomic Contribution to the Biotransformation of Trihexyphenidyl and Development of a Precision Dosing Model for Children With Dystonia and Cerebral Palsy","TRIKE2","Inclusion Criteria:\n\n* Ages 5-17 years of age\n* Diagnosis of cerebral palsy and dystonia causing interference\n* Parent\u002Flegal guardian of a child with a diagnosis of cerebral palsy and dystonia\n* Parent\u002Flegal guardian is willing and able to provide informed permission\u002Fassent for the study\n\nExclusion Criteria:\n\n* Previously or currently taking trihexyphenidyl\n* Patients turning 18 years of age within the study period (16 weeks from Study Day 1)\n* A language barrier for the patient that precludes communication and\u002For the ability to complete study-related requirements","ALL","5 Years","17 Years",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","This study looks at how a medicine called trihexyphenidyl works in children with dystonic cerebral palsy. The study aims to understand how trihexyphenidyl is broken down and used in the body of pediatric patients and whether this is impacted by a person's genetics. Information from this study will also be used to design future clinical trials.",[28,29,30,31,32,33,34,35],"Pediatric Disorder","Genetic Predisposition","Dystonia, Secondary","Dystonia","Cerebral Palsy, Dystonic-Rigid","Cerebral Palsy, Dyskinetic","Trihexyphenidyl Adverse Reaction","Pharmacogenomic Drug Interaction",[37,38,31,39,40],"Pediatric","Cerebral Palsy","Pharmacogenomics","Trihexyphenidyl","RECRUITING","2026-06-19",{"date":44,"type":45},"2026-06-24","ACTUAL",{"date":47,"type":45},"2024-10-15",{"date":49,"type":22},"2029-12-31",{"name":51,"class":52},"Children's Mercy Hospital Kansas City","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":23,"phases":65,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":53},"100518873","focused-ultrasound-pallidotomy-for-dyskinetic-cerebral-palsy-in-pediatric-and-young-adult-subjects-100518873","NCT06036199","Focused Ultrasound Pallidotomy for Dyskinetic Cerebral Palsy in Pediatric and Young Adult Subjects","Safety and Impact on Quality of Life of Focused Ultrasound Pallidotomy for Dyskinetic Cerebral Palsy in Pediatric and Young Adult Subjects","Inclusion Criteria:\n\n* The treating physician has chosen GPi-DBS or pallidotomy for the treatment of the secondary dystonia caused by cerebral palsy in this patient\n* Patient and\u002For legal representative, if the patient is underaged or not capable to give consent himself, have chosen pallidotomy as treatment\n* The consent to participate in the trial of the underaged patient, if he is capable to understand the study requirements, is required\n* Age at enrolment 8-22 years\n* Diagnosis of secondary dystonia due to cerebral palsy caused by perinatal hypoxic injury\n* Anti-dystonic pharmacotherapy insufficient\n* Stable anti-dystonic medication over the last 30 days\n* Globus pallidus internus (pars posterior) and thalamus (motor part) intact on MRI (not older than 2 years - if possible)\n* No fixed severe skeletal deformations with loss of function, which need immediate orthopaedic surgical intervention\n* Sufficient compliance of the patient or the legal representative if the patient is underaged or not capable to give consent himself to take part in the study\n* Informed consent to take part in the study from patient and\u002For legal representative if the patient is underaged or not capable to give consent himself\n* Patient and\u002For legal representative if the patient is underaged or not capable to give consent himself, understands the study requirements and the treatment procedures and provides written informed consent before any study-specific tests or procedures are performed\n\nExclusion Criteria:\n\n* Patients with known primary (e.g. DYT1) or idiopathic dystonia\n* Severe axial hypotonia with total loss of head control (e.g. absence of control at \"upper thoracic level\" in the SATCo score) (medication effect excluded)\n* Fixed hemi-dystonia\n* Severe spasticity in knee- and elbow-flexors and -extensors (Modified Ashworth Scale \\>3)\n* Fixed severe skeletal contractions with loss of function which require immediate orthopaedic surgical intervention\n* Patients with other severe concurrent neurological disease (e. g. brain tumor, neurodegenerative diseases, trauma etc.)\n* Condition likely to require use of MRI in the future\n* Any intracranial abnormality or medical condition that would contraindicate DBS surgery\n* Any findings in neuropsychological screening assessments that would contraindicate DBS surgery\n* Any current drug and \u002F or alcohol abuse\n* Any history of frequent grand-mal seizures without response to anticonvulsive treatment\n* Any other active implanted device (e.g. Cochlear implant, pacemaker), whether turned on or off, would be allowed provided that they do not interfere with functioning of the device.\n* The presence of DBS leads due the risks of these ferromagnetic devices in the MRI environment.\n* A history of neurostimulation intolerance in any area of the body.\n* Currently on any anticoagulant medications that cannot be discontinued during perioperative period.\n* Any significant medical condition that is likely to interfere with study procedures or likely to confound evaluation of study endpoints, including any terminal illness with survival \\\u003C24 months.\n* Participation in another drug, device, or biologics trial concurrently or within the preceding 30 days; any other trial participation should be approved by the Principal Investigator.\n* A female that is breastfeeding or of childbearing potential with a positive urine pregnancy test or - if a person is sexually active - not using sufficient contraception with a Pearl Index of less than 1% including all forms of hormonal contraception (\"antibaby-pill\", hormonal plaster, NuvaRing®, Implanon®, hormonal depot injections, contraceptive coil), the tubal ligature (female sterilization). Alternatively, the female of child bearing potential is sexually abstinent.\n* Subjects who have contraindications to anesthesia, in the judgment of the attending anesthesiologist\n* Subjects who are unwilling or unable to undergo general anesthesia\n* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the subject or the quality of the data.\n* Minimum head circumference \\\u003C 49cm\n* Skull Density Ratio (SDR) \\\u003C0.40.","8 Years","22 Years",{"count":64,"type":22},10,[66],"NA","The primary objective of the proposed study is to evaluate the safety of ExAblate Transcranial MRgFUS as a tool for creating bilateral or unilateral lesions in the globus pallidus (GPi) in patients with treatment-refractory secondary dystonia due to dyskinetic cerebral palsy",[33,69],"Secondary Dystonia",[71,72],"High intensity focused ultrasound (HIFU)","Pallidotomy","2026-06-09",{"date":75,"type":45},"2026-06-11",{"date":77,"type":45},"2024-01-26",{"date":79,"type":22},"2028-08",{"name":81,"class":52},"Children's National Research Institute",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":94,"phases":4,"briefSummary":95,"conditions":96,"keywords":119,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":53},"100630855","intensive-multimodal-neurorehabilitation-targeting-neuroplasticity-in-pediatric-neurodevelopmental-and-chromosomal-disorders-100630855","NCT07493096","Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disorders","Functional and Neurodevelopmental Outcomes Following Intensive Multimodal Neurorehabilitation in Pediatric Patients With Neurodevelopmental Disorders, Including Chromosomal Abnormalities","GEN-HOPE","Inclusion Criteria:\n\n* Pediatric participants between approximately 4 and 12 years of age at the time of enrollment.\n* Diagnosed with or presenting with neurodevelopmental, neurologic, or genetic conditions, including but not limited to:\n\n  * cerebral palsy\n  * autism spectrum disorder\n  * developmental delay\n  * hypoxic ischemic encephalopathy (HIE)\n  * traumatic brain injury\n  * sensory processing disorder\n  * chromosomal or genetic abnormalities\n  * Demonstrate functional impairments in one or more neurodevelopmental domains, including:\n* motor coordination or motor planning\n* sensory processing\n* attention or executive functioning\n* oculomotor or visual processing\n* communication\n* emotional or behavioral regulation\n* activities of daily living\n* Enrolled in and able to participate in a two-week intensive therapy program consisting of approximately 2.5 hours per day\u002F 5 days per week\n\n  * Able to complete baseline and post-program clinical assessment using clinician-observed or caregiver-reported measures.\n  * Parent or legal guardian able to provide informed consent and participate in reporting functional outcomes when applicable.\n\nExclusion Criteria:\n\n* Medical instability or acute medical condition that would prevent safe participation in an intensive therapy program.\n* Severe uncontrolled seizure activity or other neurologic condition that would interfere with participation in structured therapeutic activities, as determined by the treating clinician.\n* Behavioral or psychological conditions that would prevent safe engagement in the therapy environment despite appropriate support.\n* Inability to attend or complete the full two-week intensive program.\n* Lack of sufficient baseline or post-intervention data to assess change in functional performance.\n* Concurrent participation in another structured intervention or clinical study that would confound interpretation of functional outcomes, at the discretion of the investigator.","4 Years","12 Years",{"count":93,"type":22},100,"OBSERVATIONAL","This observational study evaluates functional and developmental outcomes in pediatric participants undergoing a two week intensive multimodal neurorehabilitation program. The program is designed for children with neurodevelopmental disorders, including but not limited to cerebral palsy, autism spectrum disorder, developmental delay, hypoxic ischemic encephalopathy (HIE), and chromosomal or genetic abnormalities.\n\nParticipants receive individualized therapy sessions for approximately 2.5 hours per day over a two week period. The intervention is not standardized but is tailored to each child's specific needs and may include components such as sensory integration, motor planning, reflex integration, oculomotor training, executive functioning activities, communication support, and other brain based therapeutic approaches.\n\nThe purpose of this study is to observe changes in functional abilities, including attention, motor coordination, emotional regulation, communication, and activities of daily living. Outcomes are assessed using clinician observation and parent reported changes before and after the intensive program, with limited follow-up when available.\n\nThis study does not assign participants to a specific treatment as part of a research protocol. Instead, it collects real world data from children already participating in a clinical therapy program to better understand potential benefits of intensive, individualized neurorehabilitation approaches.",[97,98,99,100,101,102,103,104,33,105,106,107,108,109,110,111,112,113,114,115,116,117,118],"Neurodevelopmental Disorders","Neurodevelopmental Disorders (NDD)","Neurodevelopmental Disorders and Developmental Abnormalities","Developmental Delay (Disorder)","Cerebral Palsy (CP)","Cerebral Palsy Hemiparetic Cerebral Palsy Spasticity Gait Disorders, Neurologic Postural Balance Impairment","Cerebral Palsy Infantile","Cerebral Palsy Spastic Hemiplegic","Autism Spectrum Disorder","Autism Spectrum Disorder (ASD","Hypoxic Ischemic Encephalopathy","Hypoxic Ischemic Encephalopathy (HIE)","Traumatic Brain Injury (TBI)","Sensory Processing Disorder","Chromosomal Abnormalities","Genetic Disorders","Down Syndrome (Trisomy 21)","Fragile X Syndrome (FXS)","RETT Syndrome With Proven MECP2 Mutation","Williams Syndrome","22q11.2 Deletion Syndrome","Sensorimotor Integration",[120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,97,138,139,140,141,142,143],"Photobiomodulation","Low-Level Laser Therapy","Vibration Therapy","Tactile Stimulation","Cognitive Training","Behavioral Therapy","Intensive Therapy","Pediatric Neurorehabilitation","Multimodal Therapy","Neuroplasticity","Sensory Integration","Reflex Integration","Motor Planning","Executive Function","Emotional Regulation","Functional Outcomes","Activities of Daily Living","High Frequency Therapy","Rehabilitation","Child Development Disorders","Occupational Therapy","Physical Therapy Modalities","Early Intervention","Cognitive Therapy","2026-03-19",{"date":146,"type":45},"2026-03-25",{"date":148,"type":45},"2026-03-01",{"date":150,"type":22},"2036-12-30",{"name":152,"class":52},"Healing Hope International",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":23,"phases":163,"briefSummary":164,"conditions":165,"keywords":166,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":179,"leadSponsor":181,"locationsCount":53},"100557007","family-centered-physiotherapy-in-dyskinetic-cerebral-palsy-100557007","NCT06532513","Family-Centered Physiotherapy in Dyskinetic Cerebral Palsy","Examination of the Effects of Family-Centered Goal-Oriented Physiotherapy and Rehabilitation Application on Body Functions, Activity, Participation and Quality of Life in Severely Affected Children With Dyskinetic Cerebral Palsy","Inclusion Criteria:\n\n1. Being in the age range of 5-18 years\n2. Having a diagnosis of Dyskinetic Cerebral Palsy (DSP) confirmed by a pediatric neurologist\n3. Being classified with a gross motor function level of IV-V using the Expanded and Revised Gross Motor Function Classification System (GMFCS E\\&R)\n4. Having a Manual Ability Classification System (MACS) classification of manual ability level IV-V\n5. Having a Communication Function Classification System (CFCS) communication function level of I-II-III\n6. For volunteers participating through Zoom and Whatsapp applications, having computer literacy and these applications installed on their devices\n\ne. Continuing routine physiotherapy and rehabilitation programs.\n\nExclusion Criteria:\n\n1. Having difficulty understanding and following instructions\n2. Having severe visual impairments\n3. Having undergone orthopedic or brain surgery interventions in the last 12 months.","18 Years",{"count":162,"type":22},24,[66],"This study aimed to examine the impact of family centered, goal-oriented physiotherapy and rehabilitation on body function, activity, participation, and quality of life in severely affected children with dyskinetic cerebral palsy (DCP). The first assessment was conducted and recorded for all patients at the beginning of the study. Subsequently, the study group was taught family centered physiotherapy practices in addition to routine physiotherapy for 10 weeks to be performed at home. The control group only received routine physiotherapy. Weekly remote monitoring, regular meetings, and a second assessment at the 10th week were conducted. The study concluded with all face-to-face assessments.\n\nAccording to the research protocol, the primary aim of this study was to evaluate the effectiveness of a 10-week family centered physiotherapy application. The goal of this intervention was to improve movement and posture, thereby enhancing daily activities and quality of life. The primary endpoint of the study was to determine the impact of family physiotherapy application taught to families during the 10-week education period.\n\nThis study was conducted at the Faculty of Physical Therapy and Rehabilitation, Hacettepe University. This study aimed to structure and define a family centered, goal-oriented, personalized physiotherapy, and rehabilitation application for the treatment of children with cerebral palsy. One of the significant objectives of this study was to examine the effects of this intervention within the framework of the International Classification of Functioning, Disability, and Health (ICF) on body function, activity, participation, and quality of life. The study protocol started with evaluations from patients after obtaining approval from the ethics committees.\n\nThe study will be completed within a follow-up period of four months without treatment, including the remote monitoring process. The results of this study aimed to provide valuable information about the effectiveness of family centered physiotherapy application in severely affected children with dyskinetic cerebral palsy.",[33],[167,168,169,138,170,136,171,172,173,174],"Dyskinetic Cerebral Palsy","Family-Centered Care","Physiotherapy","Body Functions","Participation","Quality of Life","Children's Health","Motor Skills Disorders","2025-03-30",{"date":177,"type":45},"2025-04-03",{"date":47,"type":45},{"date":180,"type":22},"2025-07-01",{"name":182,"class":52},"Hacettepe University"]